Why this biotech startup is going after rare neurological diseases
Courtesy Ovid Therapeutics
A decade ago, there were just two cancer drug programs exploring a way to harness the body's immune system so it could better attack tumor cells. One of them was on the verge of shutting down.
Researchers had noticed that, right off the bat, tumors were growing instead of shrinking, Dr. Jeremy Levin, previously an SVP at competing company Bristol-Meyers Squibb, told Business Insider.
But, Levin recounted, that was actually just the white cells going in to attack the tumor ... Читать дальше...